CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity

Chimeric antigen receptor (CAR) T cell therapy has ushered in a new era in cancer treatment. Remarkable outcomes have been demonstrated in patients with previously untreatable relapsed/refractory hematological malignancies. However, optimizing efficacy and reducing the risk of toxicities have posed...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Jing Yuan, Low, Muhammed Haiqal, Chen, Yunxin, Lim, Francesca Lorraine Wei Inng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266637/
https://www.ncbi.nlm.nih.gov/pubmed/35805933
http://dx.doi.org/10.3390/ijms23136931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266637/
https://www.ncbi.nlm.nih.gov/pubmed/35805933
http://dx.doi.org/10.3390/ijms23136931

Ejemplares similares